Tags

Type your tag names separated by a space and hit enter

Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI.
Neurology 2013; 80(12):1124-32Neur

Abstract

OBJECTIVE

To compare the predictive accuracy of β-amyloid (Aβ)1-42 and total tau in CSF, hippocampal volume (HCV), and APOE genotype for Alzheimer disease (AD)-type dementia in subjects with amnestic mild cognitive impairment (aMCI) and nonamnestic mild cognitive impairment (naMCI).

METHODS

We selected 399 subjects with aMCI and 226 subjects with naMCI from a multicenter memory clinic-based cohort. We measured CSF Aβ1-42 and tau by ELISA (n = 231), HCV on MRI (n = 388), and APOE ε4 (n = 523). Follow-up was performed annually up to 5 years. Outcome measures were progression to AD-type dementia and cognitive decline.

RESULTS

At least 1 follow-up was available for 538 subjects (86%). One hundred thirty-two subjects with aMCI (38%) and 39 subjects with naMCI (20%) progressed to AD-type dementia after an average follow-up of 2.5 years. CSF Aβ1-42, tau, Aβ1-42/tau ratio, HCV, and APOE ε4 predicted AD-type dementia in each MCI subgroup with the same overall diagnostic accuracy. However, CSF Aβ1-42 concentration was higher and hippocampal atrophy less severe in subjects with naMCI compared with aMCI. This reduced the sensitivity but increased the specificity of these markers for AD-type dementia in subjects with naMCI.

CONCLUSIONS

AD biomarkers are useful to predict AD-type dementia in subjects with aMCI and naMCI. However, biomarkers might not be as sensitive for early diagnosis of AD in naMCI compared with aMCI. This may have implications for clinical implementation of the National Institute on Aging and Alzheimer's Association criteria.

Authors+Show Affiliations

Department of Psychiatry and Neuropsychology, Maastricht University, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht, The Netherlands. s.vos@maastrichtuniversity.nlNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23446677

Citation

Vos, Stephanie J B., et al. "Prediction of Alzheimer Disease in Subjects With Amnestic and Nonamnestic MCI." Neurology, vol. 80, no. 12, 2013, pp. 1124-32.
Vos SJ, van Rossum IA, Verhey F, et al. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology. 2013;80(12):1124-32.
Vos, S. J., van Rossum, I. A., Verhey, F., Knol, D. L., Soininen, H., Wahlund, L. O., ... Visser, P. J. (2013). Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology, 80(12), pp. 1124-32. doi:10.1212/WNL.0b013e318288690c.
Vos SJ, et al. Prediction of Alzheimer Disease in Subjects With Amnestic and Nonamnestic MCI. Neurology. 2013 Mar 19;80(12):1124-32. PubMed PMID: 23446677.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. AU - Vos,Stephanie J B, AU - van Rossum,Ineke A, AU - Verhey,Frans, AU - Knol,Dirk L, AU - Soininen,Hilkka, AU - Wahlund,Lars-Olof, AU - Hampel,Harald, AU - Tsolaki,Magda, AU - Minthon,Lennart, AU - Frisoni,Giovanni B, AU - Froelich,Lutz, AU - Nobili,Flavio, AU - van der Flier,Wiesje, AU - Blennow,Kaj, AU - Wolz,Robin, AU - Scheltens,Philip, AU - Visser,Pieter Jelle, Y1 - 2013/02/27/ PY - 2013/3/1/entrez PY - 2013/3/1/pubmed PY - 2013/5/15/medline SP - 1124 EP - 32 JF - Neurology JO - Neurology VL - 80 IS - 12 N2 - OBJECTIVE: To compare the predictive accuracy of β-amyloid (Aβ)1-42 and total tau in CSF, hippocampal volume (HCV), and APOE genotype for Alzheimer disease (AD)-type dementia in subjects with amnestic mild cognitive impairment (aMCI) and nonamnestic mild cognitive impairment (naMCI). METHODS: We selected 399 subjects with aMCI and 226 subjects with naMCI from a multicenter memory clinic-based cohort. We measured CSF Aβ1-42 and tau by ELISA (n = 231), HCV on MRI (n = 388), and APOE ε4 (n = 523). Follow-up was performed annually up to 5 years. Outcome measures were progression to AD-type dementia and cognitive decline. RESULTS: At least 1 follow-up was available for 538 subjects (86%). One hundred thirty-two subjects with aMCI (38%) and 39 subjects with naMCI (20%) progressed to AD-type dementia after an average follow-up of 2.5 years. CSF Aβ1-42, tau, Aβ1-42/tau ratio, HCV, and APOE ε4 predicted AD-type dementia in each MCI subgroup with the same overall diagnostic accuracy. However, CSF Aβ1-42 concentration was higher and hippocampal atrophy less severe in subjects with naMCI compared with aMCI. This reduced the sensitivity but increased the specificity of these markers for AD-type dementia in subjects with naMCI. CONCLUSIONS: AD biomarkers are useful to predict AD-type dementia in subjects with aMCI and naMCI. However, biomarkers might not be as sensitive for early diagnosis of AD in naMCI compared with aMCI. This may have implications for clinical implementation of the National Institute on Aging and Alzheimer's Association criteria. SN - 1526-632X UR - https://www.unboundmedicine.com/medline/citation/23446677/Prediction_of_Alzheimer_disease_in_subjects_with_amnestic_and_nonamnestic_MCI_ L2 - http://www.neurology.org/cgi/pmidlookup?view=long&pmid=23446677 DB - PRIME DP - Unbound Medicine ER -